Towards clinical translation of ligand-functionalized liposomes in targeted cancer therapy: Challenges and opportunities
The development of therapeutic resistance to targeted anticancer therapies remains a
significant clinical problem, with intratumoral heterogeneity playing a key role. In this context …
significant clinical problem, with intratumoral heterogeneity playing a key role. In this context …
Molecular pathogenesis of pancreatic cancer
TJ Grant, K Hua, A Singh - Progress in molecular biology and translational …, 2016 - Elsevier
Pancreatic cancers arise predominantly from ductal epithelial cells of the exocrine pancreas
and are of the ductal adenocarcinoma histological subtype (PDAC). PDAC is an aggressive …
and are of the ductal adenocarcinoma histological subtype (PDAC). PDAC is an aggressive …
Pancreatic cancer signaling pathways, genetic alterations, and tumor microenvironment: The barriers affecting the method of treatment
Genetic alterations, especially the K-Ras mutation, carry the heaviest burden in the
progression of pancreatic precursor lesions into pancreatic ductal adenocarcinoma (PDAC) …
progression of pancreatic precursor lesions into pancreatic ductal adenocarcinoma (PDAC) …
Kaempferol Inhibits Pancreatic Cancer Cell Growth and Migration through the Blockade of EGFR-Related Pathway In Vitro
J Lee, JH Kim - PloS one, 2016 - journals.plos.org
Pancreatic cancer is one of the most appalling cancers with a pessimistic prognosis. Despite
many therapies, there has been no improvement of survival rates. In this study, we assessed …
many therapies, there has been no improvement of survival rates. In this study, we assessed …
Pancreatic cancer: molecular characterization, clonal evolution and cancer stem cells
Pancreatic Ductal Adenocarcinoma (PDAC) is the fourth most common cause of cancer-
related death and is the most lethal of common malignancies with a five-year survival rate …
related death and is the most lethal of common malignancies with a five-year survival rate …
Single molecule characterization of individual extracellular vesicles from pancreatic cancer
Biofluid-accessible extracellular vesicles (EVs) may represent a new means to improve the
sensitivity and specificity of detecting disease. However, current methods to isolate EVs …
sensitivity and specificity of detecting disease. However, current methods to isolate EVs …
Recurrent oral cancer: current and emerging therapeutic approaches
Oral cavity cancer (OCC) is associated with high incidence of loco-regional recurrences,
which account for the majority of treatment failures post-surgery and radiotherapy. The time …
which account for the majority of treatment failures post-surgery and radiotherapy. The time …
[HTML][HTML] Cancer of the pancreas: molecular pathways and current advancement in treatment
Pancreatic cancer is one of the most lethal cancers among all malignances, with a median
overall survival of< 1 year and a 5-year survival of~ 5%. The dismal survival rate and …
overall survival of< 1 year and a 5-year survival of~ 5%. The dismal survival rate and …
Cetuximab conjugated temozolomide-loaded poly (lactic-co-glycolic acid) nanoparticles for targeted nanomedicine in EGFR overexpressing cancer cells
Targeted cancer therapy was designed to minimize the different challenges of cancer
chemotherapies such as resistance to treatment and systemic toxicity. Epidermal growth …
chemotherapies such as resistance to treatment and systemic toxicity. Epidermal growth …
Angiogenin/ribonuclease 5 is an EGFR ligand and a serum biomarker for erlotinib sensitivity in pancreatic cancer
Pancreatic ribonuclease (RNase) is a secreted enzyme critical for host defense. We discover
an intrinsic RNase function, serving as a ligand for epidermal growth factor receptor (EGFR) …
an intrinsic RNase function, serving as a ligand for epidermal growth factor receptor (EGFR) …